Inhibitors of RNR are widely used in clinical oncology, but the precise mechanism of how these drugs induce toxicity in cancer cells is poorly understood due to polypharmacology and off-target effects (1, 13, 15–17). The gene discussed is NR2E3; the disease is cancer.